Virbac Corporation makes animal health and pet-care products and sells them to veterinarians and retailers. For dogs and cats it makes C.E.T dental products, Allederm dermatological products, and digestive and hairball remedies. The company's Iverhart medication prevents heartworms in dogs. Virbac also makes antibiotics, dewormer, and euthanasia products. Its other brands include Biomox, Clintabs, and Vetasyl. In addition to producing its own animal health products, the company provides contract manufacturing through subsidiary PM Resources. The company is owned by Virbac SA.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

Lundbeck Inc. (formerly Ovation Pharmaceuticals) hopes to earn its applause by staying on the look-out for niche pharmaceuticals that larger drugmakers cast aside. The company's focus is on developing drugs for central nervous system (CNS) disorders, as well as cancer drugs and hospital-based therapies. Its FDA-approved products for neurological conditions include treatments for ADHD, anxiety, and seizures; the company has several CNS products in its development pipeline, such as epilepsy drugs, drug addiction therapies, and seizure medications. Among its other marketed products are several oncology drugs, as well as a treatment for lead poisoning. The company was acquired by Denmark-based H. Lundbeck in 2009.

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Celldex Therapeutics, Inc. company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines.Celldex Company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines.

Wockhardt works hard in the pharmaceutical world. The research and pharmaceutical manufacturing firm employs more than 500 scientists who focus on recombinant biopharmaceuticals, generics, and new drug discovery. Wockhardt's products include injectables, tablets, liquids, and topicals (creams and ointments) that it manufactures to sell itself and for AstraZeneca, Sanofi-Aventis, Cell Therapeutics, Schering-Plough, and other major drug companies. It operates 15 manufacturing plants in India, the UK, Ireland, France, and the US, and has filed more than 250 patents for biotechnology products. The company is a subsidiary of Khorakiwala Holdings and Investments.

Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California. Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company's other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome.

Huntingdon Life Sciences Limited, a subsidiary of Life Sciences Research, is a leading contract research organization (CRO) that tests the safety of agrochemicals, foods, flavorings, industrial chemicals, pharmaceuticals and veterinary products. Huntingdon Life Sciences also provides drug development services for biotechnology and pharmaceutical companies, including Phase I-III testing, genetic toxicology assays, and microbiological activities.

MDS Pharma Services saves drugmakers time and energy when it comes to drug discovery. The company, a subsidiary of MDS, is a provider of contract research and development services for pharmaceutical and biotechnology companies. Through facilities in the Americas, Asia, and Europe, MDS Pharma Services provides its clients with early-stage clinical research and development services, such as consulting, target discovery, lead optimization, regulatory assistance, and Phase I-phase IIa testing. It employs an international network of scientists that serve as testing investigators. MDS Pharma has been put up for sale by parent company MDS.

Amerifit Brands aims to calm the irritating tickles, hot flashes, and pains that accompany everyday life. The company develops, markets, and distributes a variety of natural, non-prescription products blended from herbs, minerals, pharmaceuticals, and vitamins. Amerifit's brands include AZO and Estroven (women's wellness), Flex Able (joint health), Sootherbs (cough and cold remedies), and Vitaball (children's multivitamin). Its products take a variety of forms, including lozenges, gumballs, gels, and pills. The company's products are primarily sold in chain drug stores and mass market retailers. Amerifit is owned by private equity firm Charterhouse Group and has agreed to be acquired by Martek Biosciences.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.